Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
Autore:
Kass, DA; Shapiro, EP; Kawaguchi, M; Capriotti, AR; Scuteri, A; deGroof, RC; Lakatta, EG;
Indirizzi:
Johns Hopkins Med Inst, Div Cardiol, Baltimore, MD 21287 USA Johns HopkinsMed Inst Baltimore MD USA 21287 ol, Baltimore, MD 21287 USA NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA NIA Baltimore MD USA 21224NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA Alteon Inc, Ramsey, NJ 07446 USA Alteon Inc Ramsey NJ USA 07446Alteon Inc, Ramsey, NJ 07446 USA
Titolo Testata:
CIRCULATION
fascicolo: 13, volume: 104, anno: 2001,
pagine: 1464 - 1470
SICI:
0009-7322(20010925)104:13<1464:IACBAN>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
BLOOD-PRESSURE MONITOR; PULSE PRESSURE; AORTIC COMPLIANCE; RADIAL TONOMETRY; HEART-FAILURE; IN-VIVO; HYPERTENSION; STIFFNESS; RISK; SPHYGMOMANOMETER;
Keywords:
ALT-711; arteries; compliance; aging; glycosylation end products, advanced; hypertension;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Kass, DA Johns Hopkins Med Inst, Div Cardiol, 600 N Wolfe St,Halsted 500, Baltimore, MD 21287 USA Johns Hopkins Med Inst 600 N Wolfe St,Halsted 500 Baltimore MD USA 21287
Citazione:
D.A. Kass et al., "Improved arterial compliance by a novel advanced glycation end-product crosslink breaker", CIRCULATION, 104(13), 2001, pp. 1464-1470

Abstract

Background-Arterial stiffening with increased pulse pressure is a leading risk factor for cardiovascular disease in the elderly. We tested whether ALT-711, a novel nonenzymatic breaker of advanced glycation end-product crosslinks, selectively improves arterial compliance and lowers pulse pressure in older individuals with vascular stiffening. Methods and Results-Nine US centers recruited and randomly assigned subjects with resting arterial pulse pressures > 60 mm Hg and systolic pressures > 140 min Hg to once-daily ALT-711 (210 mg; n=62) or placebo (n=31) for 56 days. Preexisting antihypertensive treatment (90% of subjects) was continued during the study. Morning upright blood pressure, stroke volume, cardiac output, systemic vascular resistance, total arterial compliance, carotid-femoral pulse wave velocity, and drug tolerability were assessed. ALT-711 netted a greater decline in pulse pressures than placebo (-5.3 versus -0.6 minHg at day 56; P=0.034 for treatment effect by repeated-measures ANOVA). Systolic pressure declined in both groups, but diastolic pressure fell less with ALT-711 (P=0.056). Mean pressure declined similarly in both groups (-4 mm Hg; P <0.01 for each group, P=0.34 for treatment effect). Total arterialcompliance rose 15% in ALT-711-treated subjects versus no change with placebo (P=0.015 versus ALT-711), an effect that did not depend on reduced meanpressure. Pulse wave velocity declined 8% with ALT-711 (P <0.05 at day 56,P=0.08 for treatment effect). Systemic arterial resistance, cardiac output, and heart rate did not significantly change in either group. Conclusions-ALT-711 improves total arterial compliance in aged humans withvascular stiffening, and it may provide a novel therapeutic approach for this abnormality, which occurs with aging, diabetes, and isolated systolic hypertension.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 22:18:11